OpenURL Connection Search

Select item for more details and to access through your institution.

Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S280, doi. 10.1016/j.clml.2019.07.217
By:
- Ghia, Paolo;
- Pluta, Andrzej;
- Wach, Malgorzata;
- Lysak, Daniel;
- Kozak, Tomas;
- Simkovic, Martin;
- Kaplan, Polina;
- Kraychok, Iryna;
- Illes, Arpad;
- De La Serna, Javier;
- Dolan, Sean;
- Campbell, Phillip;
- Musuraca, Gerardo;
- Jacob, Abraham;
- Avery, Eric J.;
- Lee, Jae Hoon;
- Liang, Wei;
- Patel, Priti;
- Quah, Cheng;
- Jurczak, Wojciech
Publication type:
Article
Acalabrutinib vs. Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia: ASCEND Results at ~4 Years of Follow-up.
Published in:
Acta Haematologica Polonica, 2022, v. 53, n. A, p. 33
By:
- Jurczak, Wojciech;
- Pluta, Andrzej;
- Wach, Małgorzata;
- Lysak, Daniel;
- Simkovic, Martin;
- Kriachok, Iryna;
- Illes, Arpad;
- De la Serna, Javier;
- Dolan, Sean;
- Campbell, Philip;
- Musuraca, Gerardo;
- Jacob, Abraham;
- Avery, Eric J.;
- Jae Hoon Lee;
- Usenko, Ganna;
- Min Hui Wang;
- Ting Yu;
- Ghia, Paolo
Publication type:
Article
Thrombotic thrombocytopenic purpura masquerading as preclampsia with severe features at 13 weeks' gestation.
Published in:
American Journal of Hematology, 2020, v. 95, n. 10, p. 1216, doi. 10.1002/ajh.25914
By:
- Avery, Eric J.;
- Kenney, Sean P.;
- Byers, Benjamin D.;
- McIntosh, Jennifer J.;
- Hoover, Christopher;
- Jiang, Yizhi;
- Xia, Lijun;
- Yu, Zhongxin;
- George, James N.
Publication type:
Article
Acalabrutinib vs Idelalisib plus Rituximab (IdR) or Bendamustine plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND Final Results.
Published in:
Journal of Oncology Navigation & Survivorship, 2020, v. 11, n. 11, p. 437
By:
- Ghia, Paolo;
- Pluta, Andrzej;
- Wach, Malgorzata;
- Lysak, Daniel;
- Kozak, Tomas;
- Simkovic, Martin;
- Kaplan, Polina;
- Kraychok, Iryna;
- Illes, Arpad;
- de la Serna, Javier;
- Dolan, Sean;
- Campbell, Philip;
- Musuraca, Gerardo;
- Jacob, Abraham;
- Avery, Eric J.;
- Jae Hoon Lee;
- Wang, Denise;
- Patel, Priti;
- Jurczak, Wojciech
Publication type:
Article
Lymphomatoid papulosis in a patient treated with glatiramer acetate and the glatiramoid Glatopa for multiple sclerosis: A case report.
Published in:
Journal of Central Nervous System Disease, 2021, p. 1, doi. 10.1177/11795735211053784
By:
- Shirani, Afsaneh;
- Dalton, Scott R;
- Avery, Eric J;
- Arcot Jayagopal, Lakshman;
- Meyer, Christina;
- Stuve, Olaf;
- Zabad, Rana
Publication type:
Article

Found: 5

Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study.

Acalabrutinib vs. Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia: ASCEND Results at ~4 Years of Follow-up.

Thrombotic thrombocytopenic purpura masquerading as preclampsia with severe features at 13 weeks' gestation.

Acalabrutinib vs Idelalisib plus Rituximab (IdR) or Bendamustine plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND Final Results.

Lymphomatoid papulosis in a patient treated with glatiramer acetate and the glatiramoid Glatopa for multiple sclerosis: A case report.